Alterations in phosphatase and tensin homolog (PTEN) lipid/protein phosphatase have been demonstrated in approximately 30% of patients with bladder cancer and encompass homozygous gene deletion, loss of heterozygosity (LOH), and gene mutation [24]. Here, PTEN is linked to urinary bladder carcinoma.